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p53SUMOylation is a form of post-translational modiﬁcationwhere small ubiquitin-likemodiﬁers (SUMO) are cova-
lently attached to target proteins to regulate their properties. SUMOylation has been demonstrated during cell
stress and implicated in cellular stress response. However, it is largely unclear if SUMOylation contributes to
the pathogenesis of kidney diseases, such as acute kidney injury (AKI). Here we have demonstrated a dynamic
change of protein SUMOylation in ischemic and cisplatin nephrotoxic AKI inmice. In rat kidney proximal tubular
cells (RPTC), cisplatin-induced SUMOylation was diminished by two antioxidants (N-acetylcysteine and
dimethylurea), supporting a role of oxidative stress in the activation of SUMOylation. In addition, SUMOylation
by SUMO-2/3, but not SUMO-1, was partially suppressed by piﬁthrin-alpha (a pharmacological inhibitor of
p53), supporting a role of p53 in SUMOylation by SUMO-2/3. We further examined the role of SUMOylation
during cisplatin treatment of RPTC by using ginkgolic acid (GA), a pharmacological inhibitor of SUMOylation.
Pretreatment with GA suppressed SUMOylation and importantly, GA enhanced apoptosis during cisplatin incu-
bation. Taken together, the results demonstrate the ﬁrst evidence of SUMOylation in AKI and suggest that
SUMOylation may play a cytoprotective role in kidney tubular cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Acute kidney injury (AKI), formerly termed acute renal failure (ARF),
is a major kidney disease associated with high mortality (N50%) [1,2].
The major causes of AKI include renal ischemia, sepsis, and nephrotox-
icity [3–5]. Renal ischemia occurs during hypotension, dehydration,
vascular constriction and obstruction, septic shock and operative arterial
occlusion. Nephrotoxicity can be induced by environmental toxins as
well as prescribed drugs such as cisplatin, one of the most commonly
used drugs for cancer therapy [6–8]. Pathologically, AKI is characterized
by injury and death of the cells in kidney tubules especially those in
the proximal tubules [9,10]. Although the pathogenesis of AKI has been
explored at various cellular and molecular levels [3,4], no information
on protein SUMOylation has been reported in AKI.
SUMOylation is a reversible, post-translational modiﬁcation where
small ubiquitin-like modiﬁers (SUMO) are covalently attached to lysine
residues in the target proteins [11,12]. SUMO includes a family of pep-
tide of ~11 kDa, which consists of four isoforms: SUMO-1, -2, -3, and
-4. The ﬁrst three are ubiquitously expressed in all eukaryotes, while
SUMO-4 is only expressed in human. The mature forms of SUMO-2SecondXiangyaHospital, Central
2825; fax: +1 706 721 6120.and SUMO-3 are 95% identical in sequence, thus they are often grouped
together as SUMO-2/3 [11,12].
The conjugation pathway of SUMOylation is similar to that of
ubiquitination, but SUMO conjugation involves a different cascade of
SUMO-speciﬁc enzymes: E1—activating enzyme, E2—conjugating en-
zyme (Ubc9), usually one of the several SUMO E3 ligases and SUMO-
speciﬁc proteolytic enzyme (SENPs) for deSUMOylation andmaturation
of SUMO proteins. Unlike ubiquitination, SUMOylation does not target
the protein for degradation; instead it mainly regulates protein stability,
localization, interaction and activity [11–13]. SUMOylation has been
implicated in physiological and pathological regulations. Especially,
SUMOylation has been shown to be induced by heat, hypoxic, osmotic,
oxidative, genotoxic and metabolic stresses, suggesting a potential role
of SUMOylation in cellular stress response [14–19].
The goal of this study is to determine the changes of protein
SUMOylation in experimentalmodels of AKI andgain some initial insights
into the regulation and role of SUMOylation in this disease condition.
2. Materials and methods
2.1. Cell culture
The immortalized rat kidney proximal tubular epithelial cell
(RPTC) linewas obtained fromDr. UlrichHopfer (CaseWestern Reserve
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supplemented with 10% fetal bovine serum (FBS, 5 g/ml transferrin,
5 μg/ml insulin, 1 ng/ml EGF, 4 μg/ml dexamethasone, and 1% antibiotics
as previously) [20–22].
2.2. Reagents
Cisplatin, dimethyl sulfoxide (DMSO), dimethylthiourea (DMTU),
nacetyl-cysteine (NAC), sodium azide, piﬁthrin-α and N-
ethylmaleimide (NEM) were purchased from Sigma-Aldrich (St. Louis,
MO). Ginkgolic acid (15:1) was purchased from EMD Millipore
Corporation (Billerica, MA). Carbobenzoxy-Asp-Glu-Val-Asp-7-amino-4-
triﬂuoromethyl coumarin (DEVD.AFC) and 7-amino-4-triﬂuoromethyl
coumarin (AFC)were purchased fromEnzyme Systems Products (Dublin,
CA). Enhanced chemiluminescence kit was purchased from Pierce
Biotechnology (Rockford, IL).
2.3. Antibodies
Antibodies used in this study were from the following sources:
rabbit polyclonal anti-phospho p53 (Ser-15) (1:1000), rabbit monoclo-
nal anti-SUMO-2/3 (1:1000) from Cell Signaling Technology (Danvers,
MA); rabbit polyclonal anti-Cyclophilin B (1:5000) from Abcam Inc.
(Cambridge, MA); rabbit polyclonal anti-SUMO-1 (1:1000) from Enzo
Life Sciences (Farmingdale, NY) and all secondary antibodies (1:3000)
were obtained from Jackson ImmunoResearch (West Grove, PA).
2.4. Cell injury models
(1) Cisplatin treatment of cells: HEK293 cells and RPTC were incu-
bated respectively with 50 μM and 20 μM cisplatin in culture medium
as previously [21,22]. To determine the effects of ROS inhibitors and
p53 inhibitor, the inhibitors were added during cisplatin treatment.
After incubation for an indicated time, the cells were analyzed by mor-
phology for apoptosis or harvestedwith lysis buffer to collect cell lysates
for various biochemical analyses. (2) ATP depletion: ATP depletion was
induced in RPTC by azide treatment as before [20]. Brieﬂy, RPTC were
treated with 10 mM azide in glucose-free Krebs-Ringer bicarbonate
buffer for time as indicated. After incubation, the cells were returned
to full culture medium for recovery. After recovery for an indicated
time, the whole cell lysates were collected for immunoblotting.
2.5. Animal model of AKI
C57BL/6mice were originally purchased from the Jackson Laboratory
and maintained in the animal facility of Charlie Norwood VA Medical
Center at Augusta. The experimental protocols were approved by the
Institutional Animal Care and User Committees of Charlie Norwood VA
Medical Center.
2.5.1. Cisplatin AKI [21,23,24]
Male mice of 8 to 10 weeks were injected with a single dose of
30mg/kg cisplatin by intraperitoneal injection to induce nephrotoxicity
and kidneys were collected at 1 day, 2 day and 3 days after injection.
Control animals were injected with saline.
2.5.2. Ischemic AKI [20,24,25]
Male mice of 8 to 10 weeks were anesthetized with one intraperito-
neal injection of pentobarbital sodium (50–60 mg/kg). Flank incisions
were made to expose renal pedicles for bilateral clamping for 30 min
to induce renal ischemia. For ischemia only group, kidneys were
harvested after 30 min of clamping. For reperfusion groups, clamps
were released for reperfusion and after an indicated time, kidneys
were harvested. For sham control, mice were conducted by an identical
procedure but without renal pedicle clamping. Kidneys were collected
after an indicated time for examination.2.6. Analysis of apoptosis
Apoptosis in cell cultures was analyzed by morphological examina-
tion and caspase activity measurement.
2.6.1. Morphological examination of apoptosis
In brief, after various treatments, cells were stained with 10 μg/ml
Hoechst 33342 and ﬁxed with 4% paraformaldehyde. Then phase
contrast and ﬂuorescence microscopy were used to analyze cellular
and nuclear morphologies. The typical apoptotic morphology is the for-
mation of apoptotic bodies, nuclear condensation and fragmentation,
and cellular shrinkage. The cells showing typical apoptotic morphology
were counted to determine the percentage of apoptosis. For counting,
each ﬁeld has approximately 200 cells, and ﬁve ﬁelds were counted
for each condition.
2.6.2. Caspase activity assay
Caspase activity was measured with an enzymatic assay by using
the ﬂuorogenic peptide carbobenzoxy-Asp-Glu-Val-Asp-7-amino-4
triﬂuoromethyl coumarin (DEVD.AFC), a substrate of executioner
caspases including caspase-3, -6 and -7. In brief, cell lysates were
collected in 1% Triton X-100 buffer and then added to (25 μg of pro-
tein/sample) an enzymatic reaction containing 50 μM DEVD.AFC for
60 min at 37 °C. The ﬂuorescence signal of AFC liberated by caspase
activity was measured with a GENios platereader (Tecan US Inc.) at an
excitation of 360 nm and emission of 530 nm. A standard curve was
constructed for eachmeasurement by using free DEVD.AFC. The ﬂuores-
cence reading of the enzymatic reaction was converted into the
nanomolar amount of DEVD. AFC per mg protein per hour based on
the standard curve is used as a measure of caspase activity.
2.7. Immunoblot analysis
Whole cell lysate and tissue lysate were collected in 2% SDS lysis
buffer in the presence of 20 mM N-ethylamaleimide (NEM). Brieﬂy,
protein samples were resolved under reducing conditions on 4–12%
gradient NuPAGE gels (Invitrogen, Carlsbad, CA), transferred to
polyvinylidene diﬂuoride (PVDF) membranes, blocked with 5% fat-
free milk, and then probed with speciﬁc primary antibody overnight
at 4 °C. After primary antibody incubation, the blots were washed and
incubatedwith the horseradish peroxidase (HRP)-conjugated secondary
antibody. Finally, the antigen speciﬁc signals were detected through
incubation with the enhanced chemiluminescence (ECL) kit (Pierce,
Rockford, IL). Cyclophilin B was used as loading control.
2.8. Statistical analysis
Qualitative data were expressed as means ± S.D. The statistical dif-
ferences between two groups were determined by two-sample assum-
ing equal variance t-test with Microsoft EXCEL 2007. P b 0.05 was
considered to indicate signiﬁcant differences.
3. Results
3.1. Changes in SUMOylation during renal ischemia–reperfusion
Our initial study investigated the SUMOylation change pattern in a
mouse model of renal ischemia–reperfusion. To this end, male C57BL/
6 mice of 8–10 weeks were subjected to bilateral clamping for 30 min
to induce renal ischemia, followed by 0–48 h reperfusion. Kidney tissue
lysate was collected at various time points for immunoblot analysis
using speciﬁc antibodies to SUMO-1 or SUMO-2/3 to reveal SUMO-
conjugated proteins. As shown in Fig. 1A, several SUMO-1-conjugated
proteins were detected in control kidney tissues. Upon ischemia, there
was a slight decrease in some of these protein bands. However, 8 h
reperfusion led to a dramatic increase of SUMOylation, especially at
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crease disappeared during further reperfusion of 24–48 h (Fig. 1A).
The changes in protein SUMOylation were conﬁrmed by densitometric
analysis of SUMOlyated protein smear of N72 kDa (Fig. 1B). For
SUMO-2/3, there was a slight decrease during renal ischemia followed
by a marked increase at 8 h reperfusion, and by 24–48 h, SUMOylation
returned towards the basal control level (Fig. 1C, D). These results
suggest a dynamic SUMOylation regulation during renal ischemia–
reperfusion.
3.2. SUMOylation during ATP depletion and subsequent recovery in RPTC
We further examined protein SUMOylation in cultured renal tubular
cells during ATP depletion and subsequent recovery, an in vitro model
that partially recapitulates the in vivo condition of renal ischemia–
reperfusion [26]. ATP depletion was induced by incubating RPTC in a
glucose-free buffer containing azide, a mitochondrial respiration inhibi-
tor at complex IV. After that, the cells were returned to normal culture
medium for recovery. As shown in Fig. 2, compared with control cells,
the levels of SUMOylated proteins by both SUMO-1 and SUMO-2/3
were suppressed markedly during 1–3 h of ATP depletion. Upon recov-
ery, protein SUMOylation dramatically increased to levels that were
higher than control (Fig. 2). The blotting result was veriﬁed by quantiﬁ-
cation via densitometry. The decrease of SUMOylation during ATP
depletion is consistent with the ATP-dependence of SUMO conjugation.
The induction of SUMOylation during early recovery of ATP-depleted
cells echoes the ﬁnding of in vivo renal ischemia–reperfusion shown in
Fig. 1.
3.3. Increase of protein SUMOylation in cisplatin AKI
Next, we determined whether SUMOylation occurs in cisplatin-
induced nephrotoxic AKI. In the in vitro model, RPTC were incubated
with 20 μMcisplatin. Following cisplatin incubation, an increase in glob-
al cellular SUMOylation by both SUMO-1 and SUMO-2/3 was detected
(Fig. 3A, C). Similar results were obtained in cisplatin-treated HEK293
cells (Data not shown). In vivo, male C57BL/6 mice were intraperitone-
ally injected with a single dose of 30 mg/kg cisplatin to induce AKI. AFig. 1. Changes of SUMOylation during renal ischemia–reperfusion in mice. Male C57BL/6 mice
indicated time of reperfusion. Sham control mice were subjected to an identical surgical proced
ysis of SUMO-1 (A) and SUMO-2/3 (C). The blots were reprobed for Cyclophilin B as a loadin
*P b 0.05, signiﬁcantly different from untreated control. #P b 0.05, signiﬁcantly different from tmassive rise in SUMO conjugations (both SUMO-1 and SUMO-2/3 con-
jugations) appearing as a smear at high molecular weight was detected
at Day 2 and continued to Day 3 after cisplatin treatment (Fig. 3E, G).
The induction of SUMOylation during cisplatin AKI was substantiated
by densitometry analysis of the immunoblots (Fig. 3B, D, F, H). Together,
these results demonstrate an induction of protein SUMOylation during
cisplatin nephrotoxicity.
3.4. Effects of ROS inhibitors on SUMOylation induction during
cisplatin treatment
To gain some insights into themechanismof SUMOylation induction
in AKI, we focused on cisplatin treatment. We ﬁrst examined the
involvement of ROS, because cisplatin-induced AKI is associated with
oxidative stress [27,28], which has been shown to trigger SUMOylation.
[29,30]. Speciﬁcally, we examined the effects of two antioxidants, DMTU
and NAC, which were shown to attenuate oxidative stress and protect
the cells against cisplatin-induced apoptosis in our previous work [31].
RTPC cells were incubated with 20 μM cisplatin in the absence or pres-
ence of 10mMNAC or 10mMDMTU for 8 h. As shown in Fig. 4, protein
SUMOylation was signiﬁcantly induced during cisplatin treatment
(Fig. 4A and C: lane 2), but the induction was suppressed by DMTU
(Fig. 4A and C: lane 3) or NAC (Fig. 4A and C: lane 4).We veriﬁed the re-
sults by densitometry analysis of the immunoblots from separate exper-
iments (Fig. 4B, D). These results suggest the involvement of oxidative
stress in SUMOylation induction in cisplatin AKI.
3.5. Effects of p53 inhibitor on SUMOylation induction during
cisplatin treatment
p53 signaling pathway plays a signiﬁcant role in cisplatin AKI [24,
32]. We wondered if SUMOylation induction by cisplatin is subjected
to p53 regulation. To answer this question, we examined the effects of
piﬁthrin-α, a speciﬁc pharmacologic inhibitor of p53. RTPC cells were
incubated with 20 μM cisplatin in the absence or presence of 20 μM
piﬁthrin-α for 8 h.We found that SUMO-1 conjugationwas signiﬁcantly
induced during cisplatin treatment regardless the presence of piﬁthrin-
α (Fig. 5A, B). However, the activation of SUMOylation by SUMO-2/3were subjected to bilateral clamping for 30 min to induce renal ischemia followed by an
ure but without renal pedicle clamping. Renal tissues were analyzed by immunoblot anal-
g control. (B) and (D): Densitometry analysis. Data are presented as mean ± SD; n ≥ 3.
he 8 h perfusion group.
Fig. 2. Changes of protein SUMOylation during ATP depletion and recovery in RPTC. RPTC were subjected to 10 mM azide in glucose-free Krebs buffer for 0, 1, 2, 3 h. Then the cells of 3 h
azide treatment were returned to full culture medium for 1 h or 2.5 h of recovery. Whole cell lysates were collected for immunoblot analysis of SUMO-1 (A) and SUMO-2/3 (C). The blots
were reprobed for Cyclophilin B as loading control. (B) and (D): Densitometry analysis. Data are presented as mean± SD; n≥ 3. *P b 0.05, signiﬁcantly different from untreated control.
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effect of piﬁthrin-α on p53 was veriﬁed by immunoblot analysis of
phosphorylated p53 phosphorylation at serine-15 (Fig. 5A, B). These
results indicate that p53 contributes to SUMOylation by SUMO-2/3,
but not that by SUMO-1.
3.6. Inhibition of global protein SUMOylation sensitizes RPTC to apoptosis
There is evidence that SUMOylation induction during cell stress may
act as amechanism for cell survival [33–35]. The cell biologic function ofFig. 3. . Protein SUMOylation in RPTC and kidneys during cisplatin treatment. RPTCwere incuba
collected for immunoblot analysis of SUMO-1 (A) and SUMO-2/3 (C).Male C57BL/6micewere in
3 days after cisplatin injection for immunoblot analysis of SUMO-1 (E) and SUMO-2/3 (G). The b
analysis. Data are presented as mean ± SD; n ≥ 3. *P b 0.05, signiﬁcantly different from untreaSUMOylation during cisplatin treatment was unclear. To address this
question, we tested the effect of ginkgolic acid (GA), a newly identiﬁed
SUMOylation inhibitor that directly binds to E1 to inhibit the forma-
tion of the E1-SUMO intermediate resulting in the suppression of
SUMOylation [36]. In pilot tests, we titrated the condition of GA treat-
ment and found that 2 h pretreatmentwith 100 μMGA could effectively
block SUMOylation induced by cisplatin without causing signiﬁcant
cytotoxicity (Fig. 6B, C). Compared with cisplatin-only group, 2 h
pretreatment with GA suppressed cisplatin-induced SUMOylation by
both SUMO-1 and SUMO-2/3 (Fig. 6A). Importantly, GA pretreatmenttedwith 20 μM cisplatin for 0 h, 4 h, 8 h, and 16 h. After incubation, whole cell lysateswere
jectedwith 30mg/kg cisplatin or saline as control. Renal tissueswere collected at 0, 1, 2, or
lots were reprobed for Cyclophilin B as loading control. (B), (D), (F) and (H): Densitometry
ted control.
Fig. 3. (continued).
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logical analysis of apoptosis was conﬁrmed by the measurement of
caspase activity (Fig. 6D). Taken together, these data suggest that
inhibition of SUMOylation sensitizes renal tubular cells to apoptosis,
supporting a cytoprotective role of SUMOylation in cisplatin
nephrotoxicity.Fig. 4.Effects of NAC andDMTUonprotein SUMOylation during cisplatin treatment in RPTC. RPT
(NAC) or 10 mMDMTU for 8 h. Whole cell lysate was collected for immunoblot analysis of SUM
(B) and (D): Densitometry analysis. Data are presented as mean ± SD; n≥ 3. *P b 0.05, signiﬁc
only group.4. Discussion
During the last decade, SUMOylation has been recognized as an im-
portant post-translational modiﬁcation that regulates protein stability,
localization, interaction and activity. SUMOylation has also emerged as
a major player in a broad array of cellular processes, including signalCwere treatedwith 20 μMcisplatin in the absence or presence of 10mMN-acetyl-cysteine
O-1 (A) and SUMO-2/3 (C). The blots were reprobed for Cyclophilin B as loading control.
antly different from untreated control; #P b 0.05, signiﬁcantly different from the cisplatin-
Fig. 5. Effects of piﬁthrin-α onprotein SUMOylation during cisplatin treatment in RPTC. RTPC cellswere treatedwith 20 μMcisplatin in the absence or presence of 20 μMpiﬁthrin-α for 8 h.
Whole cell lysate was collected for immunoblot analysis of SUMO-1 (A) and SUMO-2/3 (C). The blots were reprobed for Cyclophilin B as loading control. (B) and (D): Densitometry
analysis. Data are presented as mean ± SD; n ≥ 3. *P b 0.05, signiﬁcantly different from untreated control; #P b 0.05, signiﬁcantly different from the cisplatin-only group.
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nance of genome integrity and cell proliferation [37–39]. However,
SUMOylation not only is an important regulator of normal cellular pro-
cesses, but may also play a role in the pathogenesis of human diseases.
Especially, SUMOylation is known to be activated by hypoxic, osmotic,
oxidative, genotoxic and metabolic stresses [14–19]. More recent
studies provide a biological link between the SUMOylation machinery
and different human diseases, including cancer, heart failure, diabetes
as well as neurodegenerative diseases [40–43]. However, very little is
known about SUMOylation, its regulation, and pathophysiological
role(s) in renal pathophysiology, especially in AKI.
In this study, changes in global protein SUMOylation were demon-
strated in both ischemic and cisplatin nephrotoxic AKI. For ischemic
AKI, we examined renal ischemia–reperfusion in mice and ATP
depletion–recovery in RPTC. A decrease of SUMOylation was detected
during renal ischemia and ATP-depletion (Figs. 1 and 2). This decrease
was expected, because the enzymatic reaction of SUMOylation is
ATP-dependent [11,12] and, renal ischemia in vivo and ATP-depletion
in cultured tubular cells are known to result in a rapid cellular ATP
deprivation [26,44]. Upon reperfusion or recovery, there was a marked
increase or induction of SUMOylation (Figs. 1 and 2). This induction is
consistent with the recent observation of increased SUMOylation in
stroke models of the brain [45–47]. We have further demonstrated a
time-dependent SUMOylation in kidney tissues and cells of cisplatin-
induced AKI or nephrotoxicity. Together, these results provide the ﬁrst
evidence for a dynamic alteration of protein SUMOylation in AKI.
What are the underling mechanisms for the global changes in
SUMOylation in AKI? In the present study, we focused on the cisplatin
model to gain some initial clues. Our data suggest the involvement of
oxidative stress (Fig. 4). Previous studies have demonstrated a complex
relationship between oxidative stress and SUMOylation in mammalian
cells. On one hand, severe oxidative stress was shown to increaseSUMOylation, which may result from the inactivation of SUMO prote-
ases by creation of an intra- or inter-molecular disulﬁde bridge [29,
48]. On the other hand, low or moderate oxidative stress was shown
to suppress global SUMOylation by introducing a disulﬁde bond
between SUMO E1 and E2 enzymes at the catalytic cysteine residues
or stabilizing SUMO proteases by formation of a disulﬁde bond in a reg-
ulatory element [17].We speciﬁcally examined the effect of two antiox-
idants or ROS scavengers on SUMOylation during cisplatin treatment of
RPTC (Fig. 4). Oxidative stress is associated with and contributes to
cisplatin AKI [28,49–51]. Antioxidants protect renal tubular cells against
cisplatin-induced apoptosis [31,52]. In this study, we showed that both
antioxidants (NAC and DMTU) suppressed SUMOylation induction
during cisplatin treatment (Fig. 4), supporting a role of oxidative stress.
Furthermore, we observed that the change pattern of SUMOylation was
correlatedwith p53 phosphorylation or activation (Fig. 4A and C). Nota-
bly, inhibition of p53 with piﬁthrin-α partially blocked SUMO-2/3 con-
jugation, but not SUMO-1-mediated SUMOylation (Fig. 5). This ﬁnding
is intriguing and requires further in-depth investigation to understand
the p53-mediated regulatory mechanism. Together, these observations
indicate that the regulation of SUMOylation is very complex and in-
volves multiple signaling pathways.
Functionally, upregulated SUMOylation has been implicated in
cytoprotection for cell survival, at least under some stress conditions.
For example, silencing SUMO-2/3 in primary cortical neurons in-
creased cell death during transient oxygen/glucose deprivation
[35]. Lee et al. further [33] demonstrated that focal cerebral ischemic
damage is protected in Ubc9 transgenic mice through elevated global
SUMOylation. Similarly, a more recent study found that enhanced
SUMO-2/3 conjugation by down-regulating the deSUMOylation en-
zyme SENP3 in rat cortical neurons promoted cell survival after
oxygen/glucose deprivation [34]. Our present data show that suppres-
sion of global SUMOylation by GA enhances apoptosis during cisplatin
Fig. 6.Ginkgolic acid (GA) suppresses SUMOylation during cisplatin treatment and sensitizes cells to apoptosis. RTPC cells were treatedwith 20 μM cisplatin in the absence or presence of
2 h of 100 μM GA pretreatment. (A) Immunoblot. After 8 h cisplatin treatment, whole cell lysate was collected for immunoblot analysis of SUMO-1 and SUMO-2/3. (B) Cell and nuclear
morphology. After 18 h cisplatin treatment, cells were stained with Hoechst 33342 and ﬁxed with 4% paraformaldehyde. Then phase contrast and ﬂuorescence microscopes were used
to analyze cellular and nuclear morphology. (C) Percentage of apoptosis. The cells with apoptotic morphology were counted to determine the % of apoptosis. (D) Caspase activity. Cell
lysate was collected to determine caspase activity by an enzymatic assay. Data in (C) and (D) are presented as mean ± SD; n ≥ 3. *P b 0.05, signiﬁcantly different from control;
#P b 0.05, signiﬁcantly different from the cisplatin-only group.
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protective role in renal tubular cells.
There are several potential SUMOylated proteins that may be in-
volved in AKI. For example, Drp1, the mitochondrial ﬁssion protein,
contributes to cytochrome c release and apoptosis playing an impor-
tant role in AKI [53]. SUMOylation of Drp1 impairs its localization to
mitochondria and prevents mitochondrial fragmentation, cyto-
chrome c release and apoptosis [34]. IκBα is another potential target
of SUMOylation. IκBα is an inhibitor of NFκB and SUMOylation of
IκBα by SUMO2/3 facilitates its disassociation from NFκB, which allows
NFκB activation to result in a cell survival response [54]. HDAC2, a Class I
deacetylase, can be modiﬁed by SUMO-1. SUMOylated HDAC2
deacetylates p53, which blocks the transcriptional activation of
proapoptotic genes and attenuates DNA damage-induced apoptosis
[55].
In summary, the present study has demonstrated the ﬁrst evidence of
SUMOylation during ischemic and cisplatin nephrotoxic AKI. Oxidative
stress and p53 signalingmay contribute to the induction of SUMOylation.
Upon induction, SUMOylationmay play a cytoprotective role against cell
death and tissue damage in AKI.
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